Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade

Most patients with cancer either do not respond to immune checkpoint blockade or develop resistance to it, often because of acquired mutations that impair antigen presentation. Here we show that loss of function of the RNA-editing enzyme ADAR1 in tumour cells profoundly sensitizes tumours to immunot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nature
Main Authors: Ishizuka, Jeffrey J., Manguso, Robert T., Cheruiyot, Collins K., Bi, Kevin, Panda, Arpit, Vellve, Arvin Iracheta, Miller, Brian C., Du, Peter P., Yates, Kathleen B., Dubrot, Juan, Buchumenski, Ilana, Comstock, Dawn E., Brown, Flavian D., Ayer, Austin, Kohnle, Ian C., Pope, Hans W., Zimmer, Margaret D., Sen, Debattama R., Lane-Reticker, Sarah K., Robitschek, Emily J., Griffin, Gabriel K., Collins, Natalie B., Long, Adrienne H., Doench, John G., Kozono, David, Levanon, Erez Y., Haining, W. Nicholas
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7241251/
https://ncbi.nlm.nih.gov/pubmed/30559380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41586-018-0768-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados